A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma
← catalyst calendarNCT06630806 · readout in 1,731 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
87estimated
Sites
19
Countries
Australia, Canada, France +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-10-30 | actual | When the study began enrolling |
| Primary completion | 2031-05-16 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-05-16 | estimated | The whole study's end, after follow-up |
| First posted | 2024-10-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Plasma Cell Myeloma Refractory
Intervention
- Drug: SAR446523
Primary outcomes
what the primary-completion date above is the date OFIncidence of Dose Limiting Toxicities (DLTs)- Dose escalation (Part A)
measured Cycle 1 (28 days)
Overall response rate (ORR) - Dose optimization (Part B)
measured 24 months after the Last Participant In (LPI)
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed